Transition From Buphenyl to RAVICTI for the Therapy of Byler Disease

• Status: No longer available
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This is a single patient compassionate use protocol to determine whether RAVICTI will improve bile flow in a subject who previously tolerated therapy with Buphenyl.

Details

• Lead Sponsor: University of Pittsburgh
• Treatments: 4-phenylbutyric acid; Glycerol

Criteria

Inclusion Criteria:

• Byler Disease

• Cholestasis

• Tolerance of Buphenyl therapy

Exclusion Criteria:

• Allergy/Hypersensitivity to RAVICTI